In the management of IGF2‐mediated hypoglycaemia, particularly in challenging cases of tumour‐induced hypoglycaemia unresponsive to conventional therapies, Pasireotide might be a future option once more evidence in its broader efficacy is available.24 Here, IGF2 is linked to neoplasm.